Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384455 | 0.87 | GAA (0.58) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4033651 | 0.79 | GAA (0.56) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4032671 | 0.78 | GAA (0.54) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4035069 | 0.75 | GAA (0.53) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL1381658 | 0.74 | GAA (0.52) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4033096 | 0.74 | GAA (0.60) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4036850 | 0.73 | ALDH1A1 (0.52) | GAAMAPK1TSHRALDH1A1HPGD | |
| SCHEMBL4033581 | 0.72 | GAA (0.57) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL4037109 | 0.72 | GAA (0.57) | GAAMAPK1TSHRGFERALDH1A1 | |
| SCHEMBL1913207 | 0.71 | REN (0.61) | GAAMAPK1ALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487442-B1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | MERCK SERONO SA (CH) | 2010-12-01 | — | — | EP | claimed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | claimed |
| US-8415480-B2 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor | MERCK SERONO SA (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | LABORATOIRES SERONO S.A. (CH) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215749-A9 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | GAA 4853/4885MAPK1 3180/4885TSHR 188/4885 |
| US-20080255094-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | PTGER4, PTGER2, PTGER1 | GAA 4853/4885MAPK1 3180/4885TSHR 188/4885 |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | TBXA2R, CNR2, PTGDR | GAA 4869/4885MAPK1 3569/4885TSHR 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.